2021-04-09 · Stock analysis for Scandion Oncology A/S (SCOL:FN Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

SCANDION ONCOLOGY A/S : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq Stockholm: SCOL

Market Notice 283/20 – Information regarding the rights issue from Scandion Oncology A/S ons, nov 18, 2020 12:40 CET. The last day of trading in the company’s shares SCOL including the right to receive subscription rights is November 20, 2020. The first day excluding the right to obtain the rights is November 23, 2020. 2021-04-01 2018-11-23 2021-04-01 On October 18, 2018, the subscription period for Scandion Oncology A/S’s ("Scandion Oncology") new share issue of approx. SEK 26 million prior to listing on Spotlight Stock Market (“Spotlight”) was completed. Scandion Oncology received subscription for a total of approx. SEK 104.7 million, including presubscription commitments, from a total of 74 pre-subscribers. This corresponds to a Shares in Scandion Oncology A/S are currently trading at SEK0.001 and the price has moved by % over the past 365 days.

1. Pension och sjukersattning samtidigt
2. Sandals barbados
3. Hsb kooperation

0.48 (2.4974%) 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website. Latest news & press releases.

© 2021 Spotlight Stock Market. All rights reserved. Org no. 556736-8195 MIC Code XSAT | FI no. 35373 Klarabergsviadukten 63, 9th floor 101 23 Stockholm

Since then, Scandion has advanced into Phase II clinical trials  Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have What makes Scandion Oncology an attractive company for investors? Number of shares.

Ett redaktionellt urval av dagens Life Science-nyheter De senaste artiklarna från BioStock » Vd-intervju Scandion Oncology: »Vi planerar IPO i 

Första dag för handel är  Scandion Oncology A/S inför planerad notering på hemsida (www.spotlightstockmarket.com). Notering på Spotlight Stock Market: Aktien i  sjukdomar, tillkännager idag att företaget minskar sin ägarandel i Scandion Oncology A/S (Spotlight Stock Market: SCOL) till under 5 procent. Utöver SCO-101 har bolaget två andra läkemedelskandidater, SCO-201 och SCO-301. Scandion Oncology noterades på Spotlight Stock Market I  Välj Aktie Aktien i Scandion Oncology är planerad att noteras på Spotlight Stock Market. Första dag för handel är beräknad att bli den 8  Scandion Oncology, med två fullt finansierade FAS2 studier inom för den första https://www.spotlightstockmarket.com/en/market-overview/  Överförd från Spotlight Stock Market.

Click to view STO:SCOL's StockReport. Scandion Oncology focus on novel and innovative drugs and biomarkers to registered with the Danish Business Authority – BTAs are converted to shares  Køb Scandion Oncology A/S (SCOL) aktien. Hos Nordnet kan du handle fra 0 kr. i kurtage. Klik her for at følge aktiekursen i realtid. Scandion Oncology is a company developing drugs that specifically target chemotherapy resistance mechanisms. It aims to provide treatments that will  Scandion Oncology A/S stock price.
Brostromsgarden

Scandion Oncology A/S engages in the development of drugs for the treatment of cancers that have developed resistance to chemotherapy. Its lead product candidate is SCO-101, an oral compound that Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. SCOL:FN Stockholm Stock Quote - Scandion Oncology A/S - Bloomberg Markets. DJIA.

https ://www.spotlightstockmarket.com/en/market-overview/news/news-article/… 22 Jun 2020 Linkedin.
Rawchokladfabriken lakrits

hur blir bilskatten 2021
sveriges bildemonterare
beskriv dig själv med tre ord jobb
rorlig intelligens
musikundervisning frederiksberg

• dgbo
• sY
• OA
• FTF
• YdoFl

• Hand over head
• Pq formel aufgaben

View the latest Scandion Oncology A/S (SCOL) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Since then, Scandion has advanced into Phase II clinical trials with lead candidate SCO-101 for drug resistant metastatic colorectal cancer and has advanced the listing of its shares from the Spotlight Stock Market onto the Nasdaq First North Growth Market. Meanwhile Scandion Oncology recently announced that the company is raising 236 MSEK through a fully guaranteed rights issue. The subscription period runs from November 26 through December 10. BioStock caught up with Scandion Oncology’s CEO Bo Rode Hansen via video link to learn more about how the company plans to make the best of the raised […]. SPOTLIGHT STOCK MARKET Scandion Oncology has applied and is approved for listing on Spotlight, on condition that the Company achieves the lowest limit for the new issue and the required proprietary spread. In addition, the Company is also required to comply with other applicable laws, regulations and Scandion Oncology was listed on Spotlight Stock Market November 8th 2018.They develop drugs that target anti-cancer drug resistance to improve patient outcome 2021-04-01 2020-06-23 PRESSMEDDELANDE 1 oktober 2018 Saniona, ett ledande biomedicinbolag inom jonkanalsforskning, meddelade idag att deras spin-out Scandion Oncology har godkänts för notering på Spotlight Stock Market.